Bempedoic acid : new evidence and recommendations on use
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
PURPOSES OF REVIEW: Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide. Recognizing the importance of dyslipidemia treatment in the prevention of cardiovascular events has become a part of standard clinical practice. Desired values of LDL cholesterol (LDL-C) have become lower and lower in the last few decades, as evidenced by the most recent guidelines. Therefore, efforts to lower LDL cholesterol concentrations with conventional therapies and combinations of lipid-lowering therapy may not be successful in a high proportion of patients.
RECENT FINDINGS: Bempedoic acid is a novel agent, first in-class ATP Citrate Lyase (ACL) inhibitor, which targets biosynthesis of the cholesterol in the liver. Considering the results of phase 3 studies, it has been approved for sole use for dyslipidemia treatment for patients who are statin-intolerant or in combination with statin- ezetimibe for those suffering from familial hypercholesterolemia or ASCVD and are unable to reach targeted LDL-C values.
SUMMARY: Bempedoic acid has proven beneficial for further reduction of LDL cholesterol for targeted groups of patients. It is not only efficient but also a well tolerated, affordable, and available agent whose place in lipid-lowering management is yet to be fully understood with new data collected from ongoing clinical research. In this review we suggest the place of bempedoic acid in the lipid-lowering management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Current opinion in lipidology - (2023) vom: 11. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paponja, Kristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 12.12.2023 published: Print-Electronic ClinicalTrials.gov: NCT05103254 Citation Status Publisher |
|---|
| doi: |
10.1097/MOL.0000000000000911 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365759317 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365759317 | ||
| 003 | DE-627 | ||
| 005 | 20231229123604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MOL.0000000000000911 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1227.xml |
| 035 | |a (DE-627)NLM365759317 | ||
| 035 | |a (NLM)38085172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paponja, Kristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bempedoic acid |b new evidence and recommendations on use |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05103254 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a PURPOSES OF REVIEW: Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide. Recognizing the importance of dyslipidemia treatment in the prevention of cardiovascular events has become a part of standard clinical practice. Desired values of LDL cholesterol (LDL-C) have become lower and lower in the last few decades, as evidenced by the most recent guidelines. Therefore, efforts to lower LDL cholesterol concentrations with conventional therapies and combinations of lipid-lowering therapy may not be successful in a high proportion of patients | ||
| 520 | |a RECENT FINDINGS: Bempedoic acid is a novel agent, first in-class ATP Citrate Lyase (ACL) inhibitor, which targets biosynthesis of the cholesterol in the liver. Considering the results of phase 3 studies, it has been approved for sole use for dyslipidemia treatment for patients who are statin-intolerant or in combination with statin- ezetimibe for those suffering from familial hypercholesterolemia or ASCVD and are unable to reach targeted LDL-C values | ||
| 520 | |a SUMMARY: Bempedoic acid has proven beneficial for further reduction of LDL cholesterol for targeted groups of patients. It is not only efficient but also a well tolerated, affordable, and available agent whose place in lipid-lowering management is yet to be fully understood with new data collected from ongoing clinical research. In this review we suggest the place of bempedoic acid in the lipid-lowering management | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Pećin, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Reiner, Željko |e verfasserin |4 aut | |
| 700 | 1 | |a Banach, Maciej |e verfasserin |4 aut | |
| 700 | 0 | |a endorsed by the International Lipid Expert Panel (ILEP) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in lipidology |d 1994 |g (2023) vom: 11. Dez. |w (DE-627)NLM075030659 |x 1473-6535 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:11 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MOL.0000000000000911 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 11 |c 12 | ||